Literature DB >> 6173312

Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine.

N Okada, T Yasuda, T Tsumita, H Okada.   

Abstract

By incorporation of trinitrophenylamino-caproyldipalmitoylphosphatidylethanolamine (TNP-Cap-DPPE) into liposomes composed of an equimolecular mixture of dimyristoylphosphatidylcholine (DMPC) and cholesterol (TNP-Cap-liposomes), liposomes became readily lysed by guinea-pig serum (GPS) in Mg++-EGTA-GVB (gelatin veronal buffered saline containing 2 mM MgCl2 and 10 mM ethyleneglycol-bis (beta-amino-ethyl ether)N-N'-tetraacetate) as well as in GVB++ (gelatin veronal buffered saline containing 0.15 mM CaCl2 and 0.5 mM MgCl2). Since the classical complement pathway (CCP) does not work in Mg++-EGTA-GVB, TNP-Cap-liposome lysis by GPS in Mg++-EGTA-GVB was thought to be mediated by the activation of the alternative complement pathway (ACP). This conclusion was supported by observations that heating of GPS at 50 degrees impaired its lytic activity while C4-deficient GPS was capable of lytic activity, no lysis occurred in EDTA, and there was noted consumption of complement in GPS treated with TNP-Cap-liposomes at 30 degrees. For TNP-Cap-liposome lysis by GPS in Mg++-EGTA-GVB, the epitope density of the TNP hapten was required to be 5% or more of the DMPC. Changing the acyl group of the phosphatidylcholine (PC) significantly influenced the ACP activating capacity of TNP-Cap-liposome. Dipalmitoyl-PC, DMPC and distearoyl-PC facilitated the ACP activating capacity of the TNP-Cap-liposome, while dilauroyl-PC, egg-PC and dioleoyl-PC did not. Furthermore, the length of spacer between TNP and dipalmitoylphosphatidylethanolamine (DPPE) also influenced the ACP activating capacity and maximum activation was noted when the spacer was aminocaproyl. These physicochemical characteristics which increase the ACP activating capacity coincided with those reported to increase the immunogenicity of hapten-sensitized liposomes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173312      PMCID: PMC1555162     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Active vs. passive sensitization of liposomes toward antibody and complement by dinitrophenylated derivatives of phosphatidylethanolamine.

Authors:  K Uemura; S C Kinsky
Journal:  Biochemistry       Date:  1972-10-24       Impact factor: 3.162

2.  Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane.

Authors:  H Okada; T Baba
Journal:  Nature       Date:  1974-04-05       Impact factor: 49.962

3.  Effect of immunoglobulin class and affinity on the initiation of complement-dependent damage to liposomal model membranes sensitized with dinitrophenylated phospholipids.

Authors:  H R Six; K I Uemura; S C Kinsky
Journal:  Biochemistry       Date:  1973-09-25       Impact factor: 3.162

4.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

5.  A new complement inhibitor in guinea pig serum.

Authors:  H Okada; S Kawachi; K Nishioka
Journal:  Jpn J Exp Med       Date:  1969-10

6.  The effects of Cu-chlorophyllin on the active site formation of each component of guinea-pig complement.

Authors:  H Okada; K Nishioka; T Sindo
Journal:  Immunology       Date:  1969-04       Impact factor: 7.397

7.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

8.  Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1967-09       Impact factor: 5.422

9.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

10.  Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components.

Authors:  H Gewurz; H S Shin; S E Mergenhagen
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  7 in total

1.  Location of membrane-bound hapten with different length spacers.

Authors:  K Kimura; Y Arata; T Yasuda; K Kinosita; M Nakanishi
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

2.  Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum.

Authors:  N Okada; T Yasuda; T Tsumita; H Okada
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

Review 3.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.

Authors:  M H Gaber; K Hong; S K Huang; D Papahadjopoulos
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

5.  Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine.

Authors:  N Okada; T Yasuda; T Tsumita; H Okada
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

6.  The effect of immunoglobulin G1 structure on macrophage binding to supported planar lipid monolayers.

Authors:  K Kimura; M Nakanishi; M Ueda; J Ueno; H Nariuchi; S Furukawa; T Yasuda
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

7.  Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria.

Authors:  T Koga; K Kakimoto; T Hirofuji; S Kotani; H Ohkuni; K Watanabe; N Okada; H Okada; A Sumiyoshi; K Saisho
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.